Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111


Hydroxycarbamide: clinical aspects.

Ware RE.

C R Biol. 2013 Mar;336(3):177-82. doi: 10.1016/j.crvi.2012.09.006. Epub 2012 Nov 9. Review.


Hydroxyurea therapy for sickle cell anemia.

McGann PT, Ware RE.

Expert Opin Drug Saf. 2015;14(11):1749-58. doi: 10.1517/14740338.2015.1088827. Epub 2015 Sep 14. Review.


Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.

Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K.

Blood. 2002 Jan 1;99(1):10-4.


Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.

Medicine (Baltimore). 1996 Nov;75(6):300-26.


Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.

JAMA. 2003 Apr 2;289(13):1645-51. Erratum in: JAMA. 2003 Aug 13;290(6):756.


Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia.

Flanagan JM, Steward S, Howard TA, Mortier NA, Kimble AC, Aygun B, Hankins JS, Neale GA, Ware RE.

Br J Haematol. 2012 Apr;157(2):240-8. doi: 10.1111/j.1365-2141.2012.09061.x. Epub 2012 Feb 24.


Effects of hydroxyurea treatment for patients with hemoglobin SC disease.

Luchtman-Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, Lee MT, Rothman J, Rogers ZR, Owen W, Imran H, Thornburg C, Kwiatkowski JL, Aygun B, Nelson S, Roberts C, Gauger C, Piccone C, Kalfa T, Alvarez O, Hassell K, Davis BR, Ware RE.

Am J Hematol. 2016 Feb;91(2):238-42. doi: 10.1002/ajh.24255.


Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.

Blood. 1999 Sep 1;94(5):1550-4.


Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.

Aygun B, Mortier NA, Smeltzer MP, Shulkin BL, Hankins JS, Ware RE.

Am J Hematol. 2013 Feb;88(2):116-9. doi: 10.1002/ajh.23365. Epub 2012 Dec 17.


From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.

Hankins JS, Aygun B, Nottage K, Thornburg C, Smeltzer MP, Ware RE, Wang WC.

Medicine (Baltimore). 2014 Dec;93(28):e215. doi: 10.1097/MD.0000000000000215.


The effect of hydroxcarbamide therapy on survival of children with sickle cell disease.

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

Br J Haematol. 2013 Jun;161(6):852-60. doi: 10.1111/bjh.12323. Epub 2013 Apr 17.


Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Blood. 2004 Mar 15;103(6):2039-45. Epub 2003 Nov 20.


Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; BABY HUG investigators.

Lancet. 2011 May 14;377(9778):1663-72. doi: 10.1016/S0140-6736(11)60355-3.


A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.

Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE.

J Pediatr. 2001 Dec;139(6):790-6.


Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.

Brandow AM, Panepinto JA.

Am J Hematol. 2011 Sep;86(9):804-6. doi: 10.1002/ajh.22101. Epub 2011 Aug 3. No abstract available.


Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.

Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A.

Hemoglobin. 2012;36(4):323-32. doi: 10.3109/03630269.2012.697948.


Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.

Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE; Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH).

Am J Hematol. 2013 Nov;88(11):932-8. doi: 10.1002/ajh.23547. Epub 2013 Aug 30.


Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure.

McGann PT, Howard TA, Flanagan JM, Lahti JM, Ware RE.

Br J Haematol. 2011 Jul;154(1):134-40. doi: 10.1111/j.1365-2141.2011.08698.x. Epub 2011 May 4.


Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia.

Hankins JS, Wynn LW, Brugnara C, Hillery CA, Li CS, Wang WC.

Br J Haematol. 2008 Jan;140(1):80-5. Epub 2007 Nov 7.


Use of hydroxyurea in children with sickle cell disease: what comes next?

Ohene-Frempong K, Smith-Whitley K.

Semin Hematol. 1997 Jul;34(3 Suppl 3):30-41. Review.

Items per page

Supplemental Content

Write to the Help Desk